roivw - ROIVW STOCK NEWS

Roivant Sciences (Nasdaq: ROIV) has announced the pricing of an upsized public offering of 26,666,666 common shares at $7.50 each, aiming for gross proceeds of approximately $200 million. The offering will close on February 7, 2023, subject to standard conditions. An additional 3,999,999 shares may be acquired by underwriters within 30 days. The shares are offered under a previously filed registration statement with the SEC, which was declared effective on October 3, 2022. This move is part of Roivant's strategy to enhance its capital position to support ongoing operations and development.

Roivant Sciences Ltd. (Nasdaq: ROIV) has announced a public offering of $150 million in common shares, with an additional $22.5 million option for underwriters. Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, and Cantor Fitzgerald & Co. are the bookrunning managers for this offering. The shares are offered under a registration statement previously filed with the SEC, effective since October 3, 2022. Market conditions may affect the offering's completion time and terms. This announcement does not constitute an offer to sell or a solicitation to buy these securities.

Roivant Sciences (Nasdaq: ROIV) will host a live conference call and webcast on February 13, 2023, at 8:00 a.m. ET to report third-quarter financial results for the period ending December 31, 2022. The event aims to provide a corporate update and will be accessible through their website. Moreover, Roivant will participate in key investor conferences: the SVB Securities Global Biopharma Conference on February 14 and the Cowen 43rd Annual Health Care Conference on March 7, featuring discussions that highlight the company's strategic directions.

Roivant Sciences (Nasdaq: ROIV) announced promising results from the TUSCANY-2 Phase 2b study of RVT-3101, an anti-TL1A antibody for ulcerative colitis. The study found that 32% of all patients achieved clinical remission, with higher rates among biomarker-positive patients (40%). Endoscopic improvement was noted in 40% of all patients and 56% of biomarker-positive patients. RVT-3101 demonstrated a favorable safety profile and is set to proceed to registrational studies. Roivant will share more data from the chronic therapy phase in 1H 2023.

Roivant Sciences Ltd. (Nasdaq: ROIV) reported financial results for Q2 2022, emphasizing a strong performance from VTAMA with $5.0 million in revenue from over 54,000 prescriptions. The company announced its first major PBM contract, improving access to VTAMA. Cash runway has been extended into H2 2025, supported by recent capital infusions totaling $150 million. Roivant also highlighted progress in its immunology pipeline, including the completion of enrollment for a registrational trial for brepocitinib in lupus. However, a net loss of $315.9 million was reported for the quarter.

Affivant, a biotechnology company, will present a poster on AFVT-2101 at the 37th Annual Meeting of SITC on November 11, 2022. AFVT-2101 is an Innate Cell Engager designed to target folate receptor alpha on tumors, facilitating immune cell activation for tumor destruction. The poster reports findings that AFVT-2101 effectively binds to CD16A, induces potent antibody-dependent cellular cytotoxicity (ADCC), and shows minimal off-target effects. The study confirms AFVT-2101's potential as a safe and powerful therapy in preclinical settings.

Roivant Sciences announced the pricing of a public offering of 30 million common shares at $5.00 each, generating gross proceeds of $150 million. Roivant will receive approximately $100 million from the offering, while selling shareholders will obtain about $50 million. The underwriter has a 30-day option for an additional $22.5 million in shares. The offering is set to close on November 10, 2022, subject to conditions. Roivant expects its cash flow to sustain operations into the second half of 2025.

Roivant Sciences announced a proposed underwritten public offering of $150 million of common shares, with a 30-day option for the underwriter to purchase an additional $22.5 million. The offering is subject to market conditions, with no assurance on its completion or terms. Cantor Fitzgerald & Co. is the sole bookrunner for this offering. A registration statement for these securities was declared effective on October 3, 2022, and a preliminary prospectus supplement has been filed with the SEC. This announcement does not constitute an offer to sell securities.